CRL Charles River Laboratories International Inc.

Charles River Research Models in Drug Discovery Award Presented to Sonia Vallabh and Eric Minikel of the Prion Alliance

On Tuesday, September 26, 2017, James Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories International, Inc. will present the first Charles River Research Models in Drug Discovery Award to Sonia Vallabh and Eric Minikel of the Prion Alliance.

The award will be presented during the opening session of the Inaugural Charles River World Congress on Animal Models in Drug Discovery & Development, being held on September 26-27, 2017 in Boston, Massachusetts.

From Patient to Scientist

Prion diseases are a group of neurodegenerative diseases that have an incidence of about 1 in 1 million people, according to the World Health Organization. Genetic prion diseases are universally fatal and currently untreatable. In 2011, after watching her mother lose her battle with this rare disease, Vallabh learned that she had inherited the same genetic mutation.

In 2012, Vallabh and Minikel founded the Prion Alliance with the mission of facilitating the development of a treatment or cure for prion diseases by raising funds for research, advocating, and connecting patients and researchers. In 2014, Vallabh, a law school graduate, and Minikel, an urban planner, both started a PhD program at Harvard Medical School.

Today, Vallabh and Minikel work side-by-side, based at the Stuart Schreiber laboratory at the Broad Institute of MIT and Harvard where, together with a team of researchers and advisors, they have launched Prions@Broad, an initiative to discover a treatment for prion disease.

Charles River Research Models in Drug Discovery Award

In 2017, Charles River created the Charles River Research Models in Drug Discovery Award. The $50,000 award will be given annually at the World Congress on Animal Models to recognize a researcher, laboratory, or organization dedicated to supporting the development of novel therapies.

The World Congress on Animal Models is a two-day scientific program presented by Charles River, in partnership with BioPharm America™. Attendees also receive full access to BioPharm America™ and all Biotech Week Boston events. To learn more and register, visit breakthroughs.criver.com and follow #CRLworldcon on social media.

Approved Quotes

  • “Sonia and Eric’s passion and work ethic are truly extraordinary. Driven by a uniquely personal connection to this rare disease, their work toward finding a cure for genetic prion diseases will have a profound impact on an underserved patient population.” –James C. Foster, Chairman, President and CEO at Charles River
  • “We are profoundly grateful to Charles River. Drug discovery is costly, and this award will move us tangibly toward our goal of finding a cure for genetic prion diseases.” –Sonia Vallabh, Prion Scientist at the Broad Institute

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

EN
12/09/2017

Underlying

Reports on Charles River Laboratories International Inc.

Charles River Laboratories Int'l, Inc.: Update to credit analysis

Charles River's credit profile reflects its strong and consistent free cash flow, offset by its sensitivity to R&D budgets of clients and research funding availability.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Charles River Laboratories Int'l, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 23 December 2025 in which we reassessed the appropriateness of the r...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch